Prescription drug · ANDA
Neostigmine Methylsulfate NDC 71872-7271
Neostigmine methylsulfate 1 mg/mL · Injection · Intravenous · Medical Purchasing Solutions, LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 71872-7271-1 | 71872727101 | 1 VIAL, MULTI-DOSE in 1 BAG (71872-7271-1) / 10 mL in 1 VIAL, MULTI-DOSEMarketed from Sep 23, 2022 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Neostigmine Methylsulfate
- Generic name (nonproprietary)
- neostigmine methylsulfate
- Active ingredients
- Neostigmine methylsulfate — 1 mg/mL
- Dosage form
- Injection
- Route
- Intravenous
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 213074
- Marketing start
- Listing expires
- Other FDA classes
- Cholinesterase Inhibitors (Mechanism)
- Identifiers
- Product ID 71872-7271_facbe17e-4696-d5fe-e053-6394a90a8abeSPL ID facbe17e-4696-d5fe-e053-6394a90a8abeSPL set ID ea6027ca-aac5-c33a-e053-2995a90a87fcRxCUI 311936UNII 98IMH7M386UPC 0370069806012
- Pharmacologic class
- Cholinesterase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N471872727101followed by a unit qualifier and the quantityPackage 71872-7271-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
1. INDICATIONS AND USAGE Neostigmine methylsulfate injection is a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Neostigmine Methylsulfate Injection, a cholinesterase inhibitor, is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery.
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 213074
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Neostigmine Methylsulfate | Neostigmine methylsulfate 1 mg/mL | InjectionIntravenous | Caplin Steriles Limited | 65145-112 |
| Neostigmine Methylsulfate | Neostigmine methylsulfate .5 mg/mL | InjectionIntravenous | Caplin Steriles Limited | 65145-111 |
| Neostigmine Methylsulfate | Neostigmine methylsulfate .5 mg/mL | InjectionIntravenous | Somerset Therapeutics, LLC | 70069-805 |
| Neostigmine Methylsulfate | Neostigmine methylsulfate 1 mg/mL | InjectionIntravenous | Somerset Therapeutics, LLC | 70069-806 |
| Neostigmine Methylsulfate | Neostigmine methylsulfate .5 mg/mL | InjectionIntravenous | Xellia Pharmaceuticals USA LLC | 70594-069 |
| Neostigmine Methylsulfate | Neostigmine methylsulfate 1 mg/mL | InjectionIntravenous | Xellia Pharmaceuticals USA LLC | 70594-072 |